Particularly, we found out in our study that overexpression of ICAM-1, MXRA5, AURKA, and NEAT1 are associated with the activation of NPM1, Histone H3, and TP53 in patients with serous ovarian cancer who received the platinum–paclitaxel chemotherapy regimen. Here, NEAT1 is linked to ovarian serous adenocarcinoma.